| __timestamp | BioCryst Pharmaceuticals, Inc. | Eli Lilly and Company |
|---|---|---|
| Wednesday, January 1, 2014 | 7461000 | 6620800000 |
| Thursday, January 1, 2015 | 13047000 | 6533000000 |
| Friday, January 1, 2016 | 11253000 | 6452000000 |
| Sunday, January 1, 2017 | 13933000 | 6588100000 |
| Monday, January 1, 2018 | 29514000 | 5975100000 |
| Tuesday, January 1, 2019 | 37121000 | 6213800000 |
| Wednesday, January 1, 2020 | 67929000 | 6121200000 |
| Friday, January 1, 2021 | 118818000 | 6431600000 |
| Saturday, January 1, 2022 | 159371000 | 6440400000 |
| Sunday, January 1, 2023 | 213894000 | 6941200000 |
| Monday, January 1, 2024 | 8593800000 |
In pursuit of knowledge
In the competitive landscape of pharmaceuticals, operational efficiency is key. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two industry players: Eli Lilly and Company and BioCryst Pharmaceuticals, Inc., from 2014 to 2023.
Eli Lilly, a titan in the pharmaceutical world, consistently reported SG&A expenses in the billions, peaking at approximately $6.94 billion in 2023. Over the decade, their expenses showed a steady trend, reflecting a robust operational strategy.
In contrast, BioCryst, a smaller entity, exhibited a dramatic rise in SG&A expenses, from $7.46 million in 2014 to $213.89 million in 2023. This represents a staggering increase of over 2,700%, highlighting their aggressive expansion and investment in growth.
This comparison underscores the diverse strategies employed by pharmaceutical companies in managing operational costs.
Selling, General, and Administrative Costs: Eli Lilly and Company vs Pharming Group N.V.
Operational Costs Compared: SG&A Analysis of Eli Lilly and Company and Axsome Therapeutics, Inc.
Comparing SG&A Expenses: Eli Lilly and Company vs Merus N.V. Trends and Insights
SG&A Efficiency Analysis: Comparing Eli Lilly and Company and Vericel Corporation
Pfizer Inc. or BioCryst Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Breaking Down SG&A Expenses: Gilead Sciences, Inc. vs BioCryst Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Neurocrine Biosciences, Inc. and BioCryst Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Insmed Incorporated or BioCryst Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Ascendis Pharma A/S and BioCryst Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing ADMA Biologics, Inc. and BioCryst Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Bausch Health Companies Inc. and BioCryst Pharmaceuticals, Inc.
Mesoblast Limited and BioCryst Pharmaceuticals, Inc.: SG&A Spending Patterns Compared